Tocilizumab was safe and effective for RA patients in comparison to tocilizumab plus DMARD therapy.
Via Krishan Maggon
Get Started for FREE
Sign up with Facebook Sign up with X
I don't have a Facebook or a X account
Your new post is loading...
Your new post is loading...
Krishan Maggon 's curator insight,
March 16, 2015 1:18 PM
The BMJ Today reports the results of an open label pragmatic trial—the TACIT trial—that compared the impact on disability at 12 months of a TNF based strategy (as recommended by the National Institute for Health and Care Excellence) versus a combined disease modifying drug strategy, which includes methotrexate. In this study, the combination of older drugs was non-inferior to the biologic agents. In a related editorial, Pierre Miossec concludes that the TACIT trial “gives fresh hope to more patients around the world that they can achieve equal or better disease control with combinations of established, low cost, and easy to produce alternatives [to the more expensive newer biologics].” |
Krishan Maggon 's curator insight,
March 16, 2015 1:30 PM
Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial
BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h1046 (Published 13 March 2015)Cite this as: BMJ 2015;350:h1046
Krishan Maggon 's curator insight,
August 8, 2014 7:03 PM
open access full text
RA patients not responding to TNF inhibitors benefit from treatment with IL6 targeting mabs and show regression of RA disease.
Ann Rheum Dis 2014;73:1595-1597 doi:10.1136/annrheumdis-2013-205002 EditorialIL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumabYoshiya Tanaka1, Emilio Martin Mola2+Author Affiliations 1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan2Servicio de Reumatología, Hospital Universitario La Paz, Universidad Autónoma de Madrid, Paseo de la Castellana 261, Madrid, SpainCorrespondence toProfessor Yoshiya Tanaka, The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, Japan; tanaka@med.uoeh-u.ac.jpReceived 31 January 2014Revised 23 April 2014Accepted 1 May 2014Published Online First 15 May 2014 |
Clinical Rheumatology